immuno-gene therapy and molecularly-targeted agent for head and neck squamous cell carcionma

Research Project

Project/Area Number	15K10820
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Otorhinolaryngology
Research Institution	Kyoto Prefectural University of Medicine
Principal Investigator	nakano hiroshi 京都府立医科大学, 医学(系)研究科(研究院), 講師 (00405309)
Project Period (FY)	2015-04-01 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000) Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000) Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000) Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords	サイトカイン / 頭頸部扁平上皮癌 / 免疫遺伝子治療 / セツキシマブ / 分子標的薬 / 頭頸部癌 / 扁平上皮癌
Outline of Final Research Achievements	We confirmed that IL-21, IL-27, IL-28 expression gene can suppress SCCVII tumor growth with in vivo electroporation method. Moreover, we elucidated that combination therapy with Cetuximab and IL-21 or IL-28 can synergistically suppress tumor growth. In order to elucidate the mechanism, we analyzed cytotoxic activity of NK cell and CTL, but significant difference could not be apparent.

Report

(4 results)